These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30471881)

  • 1. Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto JWF
    Eur Urol; 2019 Feb; 75(2):e29-e30. PubMed ID: 30471881
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto J;
    Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO).
    Necchi A; Messina A; Briganti A
    Eur Urol; 2018 Nov; 74(5):e107-e108. PubMed ID: 30318068
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Teoh JYC; Herrmann TRW; Babjuk M
    Eur Urol; 2019 Feb; 75(2):e27-e28. PubMed ID: 30262343
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Sungmin Woo, Valeria Panebianco, Yoshifumi Narumi, Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020;3:306-315.
    Glykas I; Fragkoulis C; Kapogiannis F; Ntoumas K
    Eur Urol Oncol; 2020 Aug; 3(4):555-556. PubMed ID: 32536572
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9.
    Del Giudice F; Catto JWF; Panebianco V
    Eur Urol; 2020 Apr; 77(4):e94-e95. PubMed ID: 32005552
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100.
    Dev S
    Eur Urol; 2022 Jan; 81(1):e25. PubMed ID: 34663524
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100: Reply from the European Association of Urology Equity, Diversity, and Inclusion Task Force.
    Carmen Mir M; Greenwell T; O'Kelly F; Proietti S; Laukhtina E; Mertens L; Morgenstern S; Ouzaid I;
    Eur Urol; 2022 Jan; 81(1):e26-e27. PubMed ID: 34772550
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9.
    Teoh JY; Murphy DG; van Oort IM; Loeb S; Ribal MJ
    Eur Urol; 2021 Oct; 80(4):e101. PubMed ID: 34315625
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Ueno Y; Takeuchi M; Tamada T; Sofue K; Takahashi S; Kamishima Y; Hinata N; Harada K; Fujisawa M; Murakami T
    Eur Urol; 2019 Jul; 76(1):54-56. PubMed ID: 30922688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9.
    Fragkoulis C; Papadopoulos G; Ntoumas K
    Eur Urol; 2020 Apr; 77(4):e93. PubMed ID: 31980311
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].
    Hechler V; Rink M; Beyersdorff D; Beer M; Beer AJ; Panebianco V; Pecoraro M; Bolenz C; Salomon G
    Urologe A; 2019 Dec; 58(12):1443-1450. PubMed ID: 31741002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 15. Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Thoeny HC; Bellin MF; Comperat EM; Thalmann GN
    Eur Urol; 2018 Sep; 74(3):307-308. PubMed ID: 29960749
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260-1.
    Bessa A; Maclennan S; Enting D; Bryan R; Häggström C; Van Hemelrijck M
    Eur Urol; 2019 Aug; 76(2):e45-e46. PubMed ID: 31109813
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600.
    Casciani E; Bertini L; Gualdi G
    Eur Urol; 2009 Jan; 55(1):e2-3; author reply e4-5. PubMed ID: 18572302
    [No Abstract]   [Full Text] [Related]  

  • 20. VESICAL IMAGING-REPORTING AND DATA SYSTEM - A NEW APPROACH TO BLADDER CANCER STAGING.
    Jakimów K; Sznajder K
    Wiad Lek; 2022; 75(5 pt 2):1384-1389. PubMed ID: 35758462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.